The researchers found that 8% of respondents reported that nothing would bring them back. HealthDay News — Adequate staffing tops the list of factors that can help hospitals reattract the registered ...
Phase 3 results suggest intravenous vedolizumab is effective and safe for clinical remission in pediatric patients with moderate to severe UC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results